Latest News

The emerging data suggest a potential adjunctive strategy to target microbial drivers of head and neck squamous cell carcinoma.

Large real-world analysis supports potential renal and survival benefits of urate-lowering therapy in patients with chronic kidney disease and hyperuricemia.

The actions will support the development of psychedelic-based therapies for PTSD, depressive disorders, and substance use disorders.

Sports Pharmacy Summit unites global experts on anti-doping, supplement safety, and data-driven performance to protect athlete health.

The reclassification of medical marijuana to Schedule III marks a major policy shift that expands research and introduces new potential health care challenges.

The treatment's approval was supported by positive evidence from the phase 1/2 CHORD clinical trial.

Emerging data found that initiating low-dose aspirin at giant cell arteritis diagnosis was associated with reduced 1-year major cardiovascular events but an increased risk of major bleeding.

Extended data from ACHIEVE-4 reinforce the durability of oral GLP-1 receptor agonist therapy, with implications for long-term diabetes management and pharmacist-led care.

Lifileucel treats advanced melanoma by harvesting, expanding, and reinfusing a patient's own tumor-fighting immune cells.

Tracking PDUFA decisions and early planning can lead to safe, rapid access to new medications for patients.

Dupilumab becomes the first biologic approved for children aged 2 to 11 years with uncontrolled chronic spontaneous urticaria, marking a significant expansion in treatment options and pharmacist-led care considerations.

Performing medication reconciliations and assessing for drug interactions are examples of strategies to prevent medication errors.

A postdischarge diabetes follow-up showed me how pharmacists prevent harm by catching omissions, simplifying plans, and using technology to restore patient confidence.

Ecopipam reduces Tourette tic relapse risk by approximately 50% with durable control and no movement-related adverse effects.

AACR data show tumor molecular profiling finds actionable PIK3CA in breast and colorectal cancer, while ctDNA adds real-time monitoring in oncology.

Pharmacists play a crucial role in evaluating 505(b)(2) drugs—from ensuring oncology therapeutic equivalence to improving access and outcomes.

A large multicohort analysis highlights obesity as a modifiable risk factor for severe infectious outcomes, reinforcing the pharmacist’s role in prevention, vaccination, and chronic disease management.

Global trade disruptions and reliance on overseas manufacturing could contribute to future drug shortages, highlighting the need for proactive planning and supply chain resilience across pharmacy settings.

National certification, advanced specialization, and informatics enhance career longevity and patient safety

Phase 3 data show quarterly cemdisiran injections improve gMG symptoms, either and matches or outperforms all study end points compared to combination therapy.

Make sure your communication is respectful, personalized, and strategic for maximum benefit.